دورية أكاديمية
أعرض في EDS

Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study.

التفاصيل البيبلوغرافية
العنوان: Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study.
المؤلفون: Hashemi Madani N; Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), No. 10, Firoozeh St, Valiasr Ave, Vali-asr Sq, Tehran, Iran., Ismail-Beigi F; Case Western Reserve University, School of Medicine, Cleveland, USA., Poustchi H; Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran., Nalini M; Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran., Sepanlou SG; Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran., Malek M; Research Center for Prevention of Cardiovascular Diseases, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran., Abbasi MA; Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), No. 10, Firoozeh St, Valiasr Ave, Vali-asr Sq, Tehran, Iran., Khajavi A; Student Research Committee, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran., Khamseh ME; Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), No. 10, Firoozeh St, Valiasr Ave, Vali-asr Sq, Tehran, Iran. me.khamseh@gmail.com., Malekzadeh R; Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
المصدر: BMC cardiovascular disorders [BMC Cardiovasc Disord] 2020 Mar 05; Vol. 20 (1), pp. 113. Date of Electronic Publication: 2020 Mar 05.
نوع المنشور: Comparative Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968539 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2261 (Electronic) Linking ISSN: 14712261 NLM ISO Abbreviation: BMC Cardiovasc Disord Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Blood Glucose/*metabolism , Dyslipidemias/*blood , Fasting/*blood , Glucose Metabolism Disorders/*blood , Hypertension/*blood , Lipids/*blood, Adult ; Aged ; Biomarkers/blood ; Dyslipidemias/diagnosis ; Dyslipidemias/epidemiology ; Female ; Glucose Metabolism Disorders/diagnosis ; Glucose Metabolism Disorders/epidemiology ; Humans ; Hypertension/diagnosis ; Hypertension/epidemiology ; Iran/epidemiology ; Longitudinal Studies ; Male ; Middle Aged ; Prognosis ; Risk Assessment ; Risk Factors ; Time Factors
مستخلص: Background: Whether pre-diabetes in the absence of hypertension (HTN) or dyslipidemia (DLP) is a risk factor for occurrence of major adverse cardiovascular events (MACE) is not fully established. We investigated the effect of impaired fasting glucose (IFG) alone and in combination with HTN, DLP or both on subsequent occurrence of MACE as well as individual MACE components.
Methods: This longitudinal population-based study included 11,374 inhabitants of Northeastern Iran. The participants were free of any cardiovascular disease at baseline and were followed yearly from 2010 to 2017. Cox proportional hazard models were fitted to measure the hazard of IFG alone or in combination with HTN and DLP on occurrence of MACE as the primary endpoint.
Results: Four hundred thirty-seven MACE were recorded during 6.2 ± 0.1 years follow up. IFG alone compared to normal fasting glucose (NFG) was not associated with an increase in occurrence of MACE (HR, 0.87; 95% CI, 0.19-4.02; p, 0.854). However, combination of IFG and HTN (HR, 2.88; 95% CI, 2.04-4.07; p, 0.000) or HTN + DLP (HR, 2.98; 95% CI, 1.89-4.71; p, 0.000) significantly increased the risk for MACE. Moreover, IFG + DM with or without HTN, DLP, or both was also associated with an increase in the incidence of MACE.
Conclusion: IFG, per se, does not appear to increase hazard of MACE. However, IFG with HTN or HTN + DLP conferred a significant hazard for MACE in an incremental manner. Moreover, IFG without HTN, adjusted for DLP, can be associated with an increase in the risk for CVD- death.
References: Eur J Prev Cardiol. 2017 Jul;24(11):1181-1189. (PMID: 28447480)
Diabetes Care. 2017 Jan;40(Suppl 1):S11-S24. (PMID: 27979889)
Med Clin North Am. 2011 Mar;95(2):327-39, vii-viii. (PMID: 21281836)
BMJ. 2016 Nov 23;355:i5953. (PMID: 27881363)
BMC Endocr Disord. 2012 Mar 31;12:2. (PMID: 22463676)
Lancet. 1999 Aug 21;354(9179):617-21. (PMID: 10466661)
JAMA. 1990 Jun 6;263(21):2893-8. (PMID: 2338751)
Circulation. 1995 Dec 1;92(11):3172-7. (PMID: 7586300)
Arch Intern Med. 2001 Feb 12;161(3):397-405. (PMID: 11176766)
Diabetes Care. 2013 May;36(5):1166-71. (PMID: 23248190)
Diabetes Care. 2019 Jul;42(7):1319-1325. (PMID: 31076416)
Biomed Res Int. 2017;2017:7839101. (PMID: 29238721)
FP Essent. 2015 Aug;435:11-6. (PMID: 26280340)
Hypertens Res. 2017 Sep;40(9):795-806. (PMID: 28701739)
Hypertension. 2015 Mar;65(3):525-30. (PMID: 25624343)
BMJ Open. 2018 Oct 4;8(9):e020584. (PMID: 30287603)
Lancet Diabetes Endocrinol. 2017 Jan;5(1):34-42. (PMID: 27863979)
Circulation. 1999 Jun 29;99(25):3227-33. (PMID: 10385495)
Genet Test Mol Biomarkers. 2016 Jun;20(6):322-7. (PMID: 27167462)
Indian J Endocrinol Metab. 2012 Mar;16(2):240-5. (PMID: 22470861)
JAMA. 2014 Feb 5;311(5):507-20. (PMID: 24352797)
Hypertension. 2018 Jun;71(6):1039-1046. (PMID: 29669793)
Circulation. 2007 Jul 10;116(2):151-7. (PMID: 17576864)
J Am Coll Cardiol. 2010 Mar 30;55(13):1310-7. (PMID: 20338491)
PLoS One. 2010 Jun 17;5(6):e11183. (PMID: 20567597)
N Engl J Med. 2008 Nov 20;359(21):2195-207. (PMID: 18997196)
Hypertension. 2006 Mar;47(3):410-4. (PMID: 16446387)
J Assoc Physicians India. 2016 Mar;64(3):18-21. (PMID: 27731552)
Int J Epidemiol. 2010 Feb;39(1):52-9. (PMID: 19332502)
Am Heart J. 2008 Nov;156(5):996-1002. (PMID: 19061718)
Curr Atheroscler Rep. 2016 Dec;18(12):82. (PMID: 27822682)
Diabetes Metab Res Rev. 2018 Jan;34(1):. (PMID: 28843031)
J Hypertens. 2003 Apr;21(4):707-16. (PMID: 12658016)
JAMA. 2016 Nov 15;316(19):2008-2024. (PMID: 27838722)
Circulation. 2002 Oct 15;106(16):2041-2. (PMID: 12379569)
Circulation. 2014 Oct 14;130(16):1374-82. (PMID: 25149362)
Cardiovasc Endocrinol. 2017 Feb 15;6(1):27-32. (PMID: 31646116)
Diabetes Care. 1999 Jun;22(6):920-4. (PMID: 10372242)
N Engl J Med. 2018 Aug 16;379(7):633-644. (PMID: 30110583)
فهرسة مساهمة: Keywords: Dyslipidemia (DLP); Hypertension (HTN); Impaired fasting glucose (IFG); Major adverse cardiovascular events (MACE); Pre-diabetes (pre-DM)
المشرفين على المادة: 0 (Biomarkers)
0 (Blood Glucose)
0 (Lipids)
تواريخ الأحداث: Date Created: 20200307 Date Completed: 20200929 Latest Revision: 20231113
رمز التحديث: 20240513
مُعرف محوري في PubMed: PMC7057517
DOI: 10.1186/s12872-020-01390-8
PMID: 32138676
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2261
DOI:10.1186/s12872-020-01390-8